AI Agent Index
ByHeather MacAvelia·Last verified Jun 18, 2026
Causaly logo

Causaly

3.5/ 5

by Causaly

Independently Reviewed
Visit causaly.com

Agentic AI platform for life sciences R&D with proprietary biomedical knowledge graph. Autonomous research agents for target identification and drug repositioning. Custom enterprise pricing.

From

Custom

custom

GitHub

Stars

G2

View on G2 ↗

MCP

No

Compatible

Causaly is the agentic AI platform built for pharmaceutical and biotech R&D operations. Founded in 2018 in London, the platform combines a proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships with autonomous AI research agents designed for high-stakes scientific decision-making. Causaly serves 12 of the top 20 global pharmaceutical companies, including named customers Gilead, the FDA, and the National Institute of Environmental Health Sciences. Core use cases span target identification, drug repositioning, mechanism of action investigation, safety assessment, competitive intelligence, and biomarker validation across the full drug discovery and development pipeline. Causaly is built API-first and connects natively to four integration categories. First, internal proprietary data ingestion allows pharmaceutical companies to bring their own clinical trial records, compound libraries, and research repositories directly into the platform, creating a unified evidence layer across internal and external sources. Second, a Microsoft technology partnership (announced June 2026) combines Causaly's knowledge graph and scientific reasoning with Microsoft's enterprise AI infrastructure for biopharma R&D decision workflows, currently in early customer engagement. Third, the platform supports MCP as a client, enabling research agents to connect to external data sources and agentic AI frameworks. Fourth, the biomedical knowledge graph integrates data from published scientific literature, clinical databases, and regulatory filings, updated with more than four million data points monthly. Notable gaps for teams evaluating the platform: Causaly does not publish native integrations with EHR systems such as Epic or Cerner, clinical trial management platforms such as Veeva Vault or Medidata, or general-purpose collaboration tools. Causaly is enterprise-only with no public self-serve pricing. No pricing page exists on the website; all contracts are sales-led and billed annually. The platform does not offer trial access, freemium tiers, or individual researcher pricing. Contact the sales team via the demo request form on causaly.com. Causaly is not designed for individual academic researchers, small biotech startups, or teams that need accessible self-serve literature tools. Elicit (from $12/month) covers structured systematic reviews at accessible pricing with a self-serve academic model. Scite.ai (from $12/month) provides citation analysis and smart reference verification for individual researchers. Semantic Scholar delivers AI-assisted academic search for free via the Allen Institute for AI. ResearchRabbit is free for academic users and maps citation networks without enterprise overhead. For general-purpose AI research rather than pharma-specific evidence synthesis, Gemini Deep Research (from $19.99/month) and ChatGPT Deep Research (from $20/month) handle broad research tasks at a fraction of the cost and with no sales process required. Causaly provides no value outside life sciences R&D and is not a fit for organizations with diverse research needs spanning multiple domains. In Q2 2026, Causaly launched Scientific Workflows (May 2026), extending the platform from ad-hoc AI research queries into governed, repeatable, end-to-end agentic automations that codify expert research processes for entire R&D teams, directly addressing the reproducibility gap in pharmaceutical R&D where output quality has historically varied by individual scientist. The Microsoft joint solution (June 2026) is in early biopharma customer engagement. Documented customer outcomes include a 5x productivity improvement over PubMed for target identification (ProQR, February 2025 case study) and a 75% reduction in proposal time during a disease area transition (a top 10 global life sciences company, April 2026 case study). The platform holds ISO 27001 certification. Causaly Agentic Research launched in September 2025 as the AI agent framework powering the current product suite. The knowledge graph adds more than four million data points monthly from biomedical literature and regulatory sources.

Pricing

custom

Segment

enterprise

Setup

moderate

Verified

Jun 18, 2026

Transparency

Quote Only

Contract

Annual Only

Data training

Not Disclosed

Autonomy

Human Required

Capabilities

literature-reviewsystematic-reviewdata-analysiscitationsdeep-research

Pros & Limitations

Editorial assessment

Pros

  • Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
  • Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
  • Agentic AI agents purpose-built for pharmaceutical R&D use cases including target identification, drug repositioning, mechanism of action investigation, and safety assessment produce outputs with traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

  • Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
  • Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
  • Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/month) or ChatGPT Deep Research ($20/month) substantially more cost-effective outside pharma R&D workflows.

Technical Details

Deployment
web
Model architectureProprietary
Avg setup time8-16 weeks (sales-led discovery, biomedical knowledge graph configuration, AI agent setup for R&D use cases, integration with pharmaceutical databases, R&D team rollout)
Autonomous rateAI agents autonomously execute multi-step research workflows within governed guardrails, including target identification, evidence synthesis, and competitive intelligence. R&D scientists review and approve all decision-supporting outputs. Scientific Workflows (May 2026) extends this to governed, repeatable end-to-end agentic automations for entire R&D teams.
Integrations
PDF importsPubMedMendeley
Security
ISO 27001

Similar agents

Rating

3.5/ 5

Editorial score

How we score this →

Score breakdown

AutCap 4 · IntDepth 4 · PriceTrans 2 · IndEvid 3 · SetupAcc 1 = 3.45

Industries

PharmaHealthcare

Leave a review

Never displayed publicly.

Agent Stacks

See workflow stacks that feature Causaly.

Compare

Related Content

Is this your tool?

Claim this listing for free to verify your details. Upgrade to Vendor Managed for priority verification and homepage placement.

Claim listing →

Free · Every Two Weeks

AI Agent Price & Rating Tracker

Price changes, new agent launches, acquisitions, and rating updates across 330+ AI agents, verified against live vendor data every 14 days.

No spam. Unsubscribe anytime. We never share your email.